3 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Recruiting 2 |
Follow Enavogliflozin 0.3mg: new trials by email Literature Review of Enavogliflozin 0.3mg trials Research Report on Enavogliflozin 0.3mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy Enavogliflozin 0.3mg, Placebo - Amyloid Cardiomyopathy | Phase 4 | Recruiting | Seoul St. Mary's Hospital | 68 | 2026-01-06 | 2026-06-18 |
| Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia Envlo Tablet, Envlomet SR Tablet - Diabetes Mellitus, Type 2 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 12000 | 2024-12-03 | 2025-01-23 | |
| ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy enavogliflozin 0.3mg, enavogliflozin Placebo - Nonobstructive Hypertrophic Cardiomyopathy | Phase 4 | Recruiting | Yonsei University | 200 | 2024-10-15 | 2024-11-08 |
Amyloid Neuropathies, Familial (1) · Cardiomyopathy, Hypertrophic (1) · Diabetes Mellitus, Type 2 (1)
Daewoong Pharmaceutical Co. LTD. (1) · Seoul St. Mary's Hospital (1) · Yonsei University (1)
South Korea (3)
In-Cheol Kim, MD (1) · Jang-Won Son, MD (1) · Jiwon Seo, MD (1) · Jong-Chan Youn, MD, PhD (1) · Sang Hoon Moon (1)